PeproMene Bio validates BAFF-R targeted CAR T-cell therapy in The Lancet with breakthrough results for relapsed B-cell lymphomas
Executive summary: PeproMene Bio published Phase 1 clinical trial results in The Lancet for its PMB-CT01 therapy, showing significant efficacy in B-cell lymphomas, including cases resistant to CD19 CAR T-cells. The results position the company's BAFF-R targeted therapy as a potential solution for patients who have failed standard CAR T-cell therapies.
Who is involved: PeproMene Bio, The Lancet.
Likely next: Transition toward Phase 2 clinical trials and potential expansion of the patient cohort.
PeproMene Bio's Phase 1 clinical trial data, published in The Lancet, demonstrates deep and durable complete responses in patients with relapsed/refractory B-cell lymphomas. Notably, the PMB-CT01 therapy showed efficacy even in patients who previously failed CD19-targeted CAR T-cell treatments. This peer-reviewed publication provides clinical validation for the company's first-in-class BAFF-R targeted approach.
What's next — scenarios
Base Case: Clinical progression (60%)
Successful Phase 2 trials lead to accelerated regulatory pathways.
- Consistent efficacy in larger patient populations
- Safety profile remains manageable in Phase 2
Upside: Strategic partnership (25%)
Big Pharma acquisition or major licensing deal for PMB-CT01.
- Positive data in expanded indications
- Significant increase in institutional investment
Downside: Safety concerns (15%)
Regulatory holds or clinical trial suspension.
- Observation of unexpected toxicity or cytokine release syndrome in later cohorts
What to watch
- Announcement of Phase 2 trial design
- Interim data from expanded clinical cohorts
- Potential partnership announcements with larger pharmaceutical firms
Timeline
- — PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results (PR Newswire)
- — PeproMene Bio announces the publication in The Lancet of Phase 1 results for PMB-CT01 (PR Newswire)
- — CREATE Medicines and WestGene Collaboration for In Vivo CAR Pipeline (PR Newswire)
Analysis — what this means
Sectors affected
- Oncology
- Cell and Gene Therapy
- Biotechnology
Key entities
Sources
- PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results — PR Newswire
- PeproMene Bio announces the publication in The Lancet of Phase 1 results for PMB-CT01 — PR Newswire
- CREATE Medicines and WestGene Collaboration for In Vivo CAR Pipeline — PR Newswire
Related cases
- PeproMene Bio's PMB-CT01 demonstrates deep remission in B-cell lymphomas even after CD19 CAR-T failure
- Investors with over $100,000 losses in Avis Budget Group must file lead plaintiff claims by Sept 29, 2026 in ongoing securities class action
- Antengene secures Australian regulatory clearance to launch a first-in-human Phase I trial of its CD19xCD3 T-cell engager ATG-201 for B-cell autoimmune disorders
- ClaimsFiler reminds Avis Budget Group investors of September 29 lead plaintiff deadline in securities class action
- Rosen Law Firm alerts Avis Budget Group investors of chance to lead securities fraud class action against Pentwater Capital Management over alleged short‑swing profits
- Rosen Law Firm invites Avis Budget investors to lead a securities fraud class action against Pentwater Capital Management over alleged short‑squeeze manipulation